Incyte (INCY) Reiterated at Buy by Stifel After FDA Response to sBLA Submission
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $120.00 price target on Incyte (NASDAQ: INCY).The analyst commented, "FDA’s issuance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
